Latest Trials Latest NewsFAQ

Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: LY3041658
Drug: Placebo

First Posted Date: 2020-07-30

Last Posted Date: 2023-04-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT04493502

Locations: 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
Skin Care Research, Inc, Hollywood, Florida, United States

and more 17 locations

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

Not Applicable

Completed

Conditions: Type 2 Diabetes
Type 1 Diabetes

Interventions: Device: IIM System
Drug: Insulin Lispro and/or Insulin Glargine

First Posted Date: 2020-07-24

Last Posted Date: 2021-01-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 67

Registration Number: NCT04484779

Locations: 🇺🇸
Rainier Clinical Research Center, Renton, Washington, United States
🇺🇸
Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States
🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States

and more 1 locations

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain

Phase 2

Completed

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Placebo
Drug: LY3016859

First Posted Date: 2020-07-17

Last Posted Date: 2023-11-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 125

Registration Number: NCT04476108

Locations: 🇺🇸
Irvine Clinical Research Center, Irvine, California, United States
🇺🇸
Martin E. Hale M.D., P.A., Plantation, Florida, United States
🇺🇸
Synexus Clinical Research, Chicago, Illinois, United States

and more 26 locations

A Study of LY3473329 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3473329

First Posted Date: 2020-07-15

Last Posted Date: 2021-12-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 86

Registration Number: NCT04472676

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

Phase 3

Withdrawn

Conditions: Ulcerative Colitis

Interventions: Drug: Mirikizumab IV
Drug: Vedolizumab IV
Drug: Placebo IV
Drug: Placebo SC
Drug: Mirikizumab SC

First Posted Date: 2020-07-13

Last Posted Date: 2021-05-06

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT04469062

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: LY3016859
Drug: Placebo

First Posted Date: 2020-07-02

Last Posted Date: 2023-11-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 117

Registration Number: NCT04456686

Locations: 🇺🇸
Irvine Clinical Research Center, Irvine, California, United States
🇺🇸
Synexus Clinical Research, Chicago, Illinois, United States
🇺🇸
PharmQuest, Greensboro, North Carolina, United States

and more 24 locations

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

Phase 1

Active, not recruiting

Conditions: Alzheimer Disease
Healthy

Interventions: Drug: LY3372993
Drug: Placebo

First Posted Date: 2020-06-30

Last Posted Date: 2024-10-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 224

Registration Number: NCT04451408

Locations: 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇯🇵
Oita University Hospital, Yufu, Oita, Japan
🇺🇸
IMIC, Inc., Miami, Florida, United States

and more 10 locations

A Study of LY3209590 in Participants With Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: LY3209590
Drug: Insulin Degludec

First Posted Date: 2020-06-29

Last Posted Date: 2022-10-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 266

Registration Number: NCT04450407

Locations: 🇦🇹
Klinik Landstraße, Vienna, Austria
🇺🇸
Diabetes and Thyroid Center of Fort Worth, Fort Worth, Texas, United States
🇺🇸
Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States

and more 49 locations

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LY3209590
Drug: Insulin Degludec

First Posted Date: 2020-06-29

Last Posted Date: 2022-11-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 278

Registration Number: NCT04450394

Locations: 🇦🇷
CEMEDIC, Buenos Aires, Argentina
🇵🇱
Centrum Kliniczno-Badawcze, Elblag, Poland
🇵🇱
Gabinety TERPA, Lublin, Poland

and more 60 locations

A Study of LY3832479 (LY-CoV016) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3832479
Drug: Placebo

First Posted Date: 2020-06-22

Last Posted Date: 2021-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT04441931

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy